These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37638213)

  • 1. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union.
    Balkhi B; Almuaither A; Alqahtani S
    Saudi Pharm J; 2023 Sep; 31(9):101738. PubMed ID: 37638213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
    Miller KL; Fermaglich LJ; Maynard J
    Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Traits, trends and hits of orphan drug designations in cystic fibrosis.
    Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
    J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
    Döring JH; Lampert A; Hoffmann GF; Ries M
    PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
    Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
    Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
    Fermaglich LJ; Miller KL
    Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.